Who is sponsoring NCT05821192?

NCT05821192 is sponsored by Ou Bai, MD/PHD.

What drugs are being tested in NCT05821192?

Interventions in NCT05821192: Rituximab, Gemcitabine, Dexamethasone, Cisplatin, PD-1 monoclonal antibody.

What condition does NCT05821192 study?

NCT05821192 studies Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma.

Is NCT05821192 still recruiting?

NCT05821192 is currently status unknown. Last updated 20 April 2023.

Last reviewed 2023-04-20 · How we verify

NCT05821192

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

Status unknown NA Last updated 20 April 2023

What this trial tests

NA trial testing Rituximab in Peripheral T-Cell Lymphoma, Not Otherwise Specified in 34 participants. Status unknown.

Timeline

23 March 2023

Primary endpoint
18 April 2023

31 December 2024

Quick facts

Lead sponsor	Ou Bai, MD/PHD
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	34
Start date	23 March 2023
Primary completion	18 April 2023
Estimated completion	31 December 2024
Sites	1 location across China

Drugs / interventions tested

Rituximab — full drug profile →
Gemcitabine (gemcitabine) — full drug profile →
Dexamethasone (dexamethasone) — full drug profile →
Cisplatin (cisplatin) — full drug profile →
PD-1 monoclonal antibody

Conditions studied

Peripheral T-Cell Lymphoma, Not Otherwise Specified — all drugs for Peripheral T-Cell Lymphoma, Not Otherwise Specified →
Angioimmunoblastic T-cell Lymphoma — all drugs for Angioimmunoblastic T-cell Lymphoma →

Sponsor

Ou Bai, MD/PHD

Who can join

Adults 18 to 70, any sex, with Peripheral T-Cell Lymphoma, Not Otherwise Specified or Angioimmunoblastic T-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A multi-center, prospective clinical study to evaluate the efficacy and safety of R-GDP plus PD-1 monoclonal antibody in the treatment of refractory or relapsed peripheral T cell lymphoma not otherwise specified and Angioimmunoblastic T-cell lymphoma, which has previously shown promising efficacy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Antibody-Based Therapies for Peripheral T-Cell Lymphoma.
Shafagati N, Paul S, Rozati S, Sterling CH. · · 2024 · PMID 39456582 · DOI 10.3390/cancers16203489

Verify or expand the search:

Other trials of Rituximab

Trials testing the same drug.

NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
NCT06965114 — Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia · Phase 1, PHASE2 · recruiting
NCT07335562 — A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versu · Phase 3 · recruiting

Other recruiting trials for Peripheral T-Cell Lymphoma, Not Otherwise Specified

Currently open trials in the same condition.

NCT06712810 — Q702 for the Treatment of Patients With Hematologic Malignancies · Phase 1 · recruiting
NCT06508463 — Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma · Phase 1 · recruiting
NCT05978141 — A Registry for People With T-cell Lymphoma · recruiting
NCT03113500 — Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma · Phase 2 · active not recruiting
NCT01787409 — Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency · NA · active not recruiting

Other Ou Bai, MD/PHD trials

Trials by the same sponsor.

NCT07493109 — Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP · Phase 3 · recruiting
NCT07493148 — Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL · Phase 2 · recruiting
NCT07525817 — A Real-World Study of Pirtobrutinib in cBTKi-Resistant/Intolerant Mature B-Cell Lymphoma · not yet recruiting
NCT05834751 — the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma · NA · unknown
NCT04661943 — Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05821192 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ou Bai, MD/PHD
Last refreshed: 20 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05821192.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing